United States Esophageal Cancer Market Size, Share, Growth, and Industry Analysis, By Cancer Type (Adenocarcinoma, Squamous Cell Carcinoma, Others (e.g., small cell carcinoma)), By Diagnosis (Endoscopy, Biopsy, Barium Swallow (Esophagram), Imaging (CT, PET, MRI)) and Forecast, 2026-2034

United States Esophageal Cancer Market Trends

Biomarker-Directed and Immunotherapy-Based Treatment Is Reshaping Clinical Practice

Precision oncology is increasing the importance of PD-L1, HER2, and other biomarker testing in treatment selection. FDA-approved pembrolizumab regimens and nivolumab-based treatment have embedded checkpoint inhibition into advanced esophageal cancer management. In KEYNOTE-590, involving 749 patients, pembrolizumab plus chemotherapy produced median overall survival of 12.4 months versus 9.8 months with chemotherapy and median progression-free survival of 6.3 months versus 5.8 months.

Administration technology is also evolving. In December 2024, FDA approved subcutaneous nivolumab-hyaluronidase across eligible nivolumab solid-tumor indications, including esophageal carcinoma and esophageal adenocarcinoma; September 2025 brought approval of subcutaneous pembrolizumab-hyaluronidase across eligible pembrolizumab indications. Meanwhile, the estimated 22,070 U.S. cases and 16,250 deaths reported for 2025 underscore continuing clinical demand despite esophageal cancer accounting for only about 1% of U.S. cancer cases.

United States Esophageal Cancer Market Drivers

Expanding Precision Oncology and Immunotherapy Utilization

Treatment intensity is being supported by checkpoint inhibitors, biomarker-guided regimens, and combination therapies for locally advanced and metastatic disease. KEYNOTE-590 randomized 749 patients 1:1 and demonstrated an overall-survival hazard ratio of 0.73 and progression-free-survival hazard ratio of 0.65 for pembrolizumab plus chemotherapy. The substantial disease burden—22,070 estimated diagnoses and 16,250 deaths in 2025—maintains demand for endoscopy, pathology, imaging, systemic therapy, surgery, and supportive care.

United States Esophageal Cancer Market Restraints

Low Incidence and Persistently High Mortality Constrain Addressable Patient Volumes

Esophageal cancer represents approximately 1% of U.S. cancer cases, with incidence around 4 cases per 100,000 people annually. Moreover, 16,250 estimated deaths against 22,070 new cases in 2025 illustrate the disease's severe mortality burden. Incidence rates declined by an average 0.4% annually from 2012 to 2021, potentially limiting patient-volume expansion even as spending per treated patient increases through advanced diagnostics and combination therapy.

United States Esophageal Cancer Market Opportunities

Companion Diagnostics and Biomarker Selection Expand Addressable Precision-Treatment Pathways

Companion diagnostics create opportunities across pathology laboratories, cancer centers, and drug-development ecosystems. In February 2026, FDA expanded the PD-L1 IHC 22C3 pharmDx indication to aid identification of esophageal or GEJ carcinoma patients for pembrolizumab treatment. In July 2026, the PD-L1 IHC 28-8 pharmDx indication was expanded for esophageal squamous cell carcinoma and esophageal adenocarcinoma in connection with nivolumab-based treatment. These developments add biomarker testing to a clinical pathway serving more than 22,000 annual U.S. cases.

Challenges in United States Esophageal Cancer Market

Complex Tumor Biology and Late-Stage Disease Complicate Treatment Optimization

The clinical landscape encompasses at least 2 dominant histologies, multiple stages from 0 through IV, and molecular markers including PD-L1 and HER2. NCI reports adenocarcinoma accounts for at least 50% of malignant esophageal lesions in its treatment review, while approximately 30% are squamous cell carcinomas. In advanced disease, KEYNOTE-590 showed median overall survival of 12.4 months with pembrolizumab plus chemotherapy versus 9.8 months in the comparator group, demonstrating progress but also the persistent difficulty of achieving durable control.

United States Esophageal Cancer Market Segmentation

The market is segmented by cancer type, diagnosis, treatment, stage, route of administration, end user, and distribution channel. Within supplied cancer-type data, adenocarcinoma holds approximately 45.12% of 2026 revenue; within diagnosis, endoscopy holds approximately 30.08%.

By Cancer Type

Adenocarcinoma is the largest subsegment, increasing from USD 2,226.32 million in 2025 to USD 2,292.22 million in 2026 and USD 2,894.71 million by 2034 at a 2.96% CAGR. Its 2026 contribution is approximately 45.12%, compared with 34.93% for squamous cell carcinoma.

Others, including small cell carcinoma, are the fastest-growing cancer-type category at a 3.40% CAGR, expanding from USD 1,013.37 million in 2026 to USD 1,324.14 million in 2034. Squamous cell carcinoma advances from USD 1,774.14 million to USD 2,236.98 million at 2.94%.

By Diagnosis

Endoscopy leads diagnosis, rising from USD 1,482.90 million in 2025 to USD 1,529.76 million in 2026 and USD 1,962.07 million by 2034 at a 3.16% CAGR. Its approximate 2026 contribution is 30.08%, ahead of barium swallow at 25.20% and biopsy at 20.92%.

Imaging comprising CT, PET, and MRI is the fastest-growing supplied diagnostic subsegment at a 3.29% CAGR, reaching USD 667.63 million by 2034 from USD 515.31 million in 2026. Biopsy grows at 3.25%, barium swallow at 3.24%, esophageal manometry at 2.90%, and blood tests at 2.76%.

By Treatment

Treatment is segmented by therapy type into chemotherapy, radiation therapy, targeted therapy, immunotherapy, surgery, endoscopic treatments, and palliative care, and by drug class into PD-1/PD-L1 inhibitors, HER2 inhibitors, VEGF inhibitors, cytotoxic agents, TKIs, antimetabolites, and others. Numerical subsegment values were not supplied; consequently, no unsupported revenue share or CAGR is assigned. Clinically, FDA evidence includes a 749-patient pembrolizumab trial and a 419-patient nivolumab ESCC trial.

By Stage, Route of Administration, End User, and Distribution Channel

Stage segmentation covers Stage 0, I, II, III, and metastatic Stage IV. Administration comprises oral, intravenous, and other routes, while end users comprise hospitals, specialty cancer centers, academic and research institutes, ASCs, and homecare settings. Distribution comprises hospital, retail, and online pharmacies. Subsegment monetary values and CAGRs were not provided, preventing defensible numerical ranking. Subcutaneous immunotherapy formulations nevertheless broaden administration options beyond conventional intravenous delivery.

United States Esophageal Cancer Market Counties Outlook

The supplied dataset provides national United States values rather than county-level revenue. Accordingly, assigning county shares, county production figures, or county CAGRs would require unsupported assumptions. Nationally, the cancer-type dataset moves from USD 4,929.84 million in 2025 to USD 5,079.73 million in 2026 and USD 6,455.83 million in 2034. Diagnosis data total USD 5,086.06 million in 2026 and USD 6,528.18 million in 2034.

The epidemiological footprint is likewise national: 22,070 estimated cases and 16,250 deaths in 2025, including 17,430 male and 4,640 female cases. County contributions and sector splits should therefore be treated as not available from the mandatory dataset rather than estimated or extrapolated.

Top players in United States Esophageal Cancer Market

1. Merck & Co., Inc.
2. Bristol Myers Squibb
3. Roche
4. AstraZeneca
5. Pfizer Inc.
6. Eli Lilly and Company
7. Amgen Inc.
8. Novartis AG
9. Johnson & Johnson
10. Astellas Pharma Inc.
11. Daiichi Sankyo Company, Limited
12. BeiGene
13. Gilead Sciences, Inc.
14. Sanofi
15. Takeda Pharmaceutical Company Limited

Top Two Companies

• Merck & Co., Inc.— A precise company revenue share cannot be calculated from the supplied market tables. Merck holds a strong clinical position through pembrolizumab-based immunotherapy. KEYNOTE-590 enrolled 749 patients and demonstrated median overall survival of 12.4 months versus 9.8 months with chemotherapy, while progression-free survival reached 6.3 months versus 5.8 months. FDA's 2026 PD-L1 22C3 companion-diagnostic labeling expansion further reinforces biomarker-linked treatment selection.
• Bristol Myers Squibb— A defensible percentage company share is not contained in the mandatory dataset and is therefore not fabricated. Bristol Myers Squibb maintains a significant competitive position through nivolumab. In ATTRACTION-3, involving 419 ESCC patients, nivolumab achieved median overall survival of 10.9 months compared with 8.4 months for taxane chemotherapy, with a hazard ratio of 0.77. Subcutaneous Opdivo Qvantig and the July 2026 PD-L1 28-8 diagnostic-label expansion strengthen its administration and biomarker ecosystem.

Recent Developments in United States Esophageal Cancer Market

• 2026:FDA expanded PD-L1 IHC 28-8 pharmDx labeling to help identify ESCC and esophageal adenocarcinoma patients for nivolumab or Opdivo Qvantig treatment.
• 2026:FDA expanded PD-L1 IHC 22C3 pharmDx labeling as an aid in selecting esophageal or GEJ carcinoma patients for pembrolizumab.
• 2025:FDA approved subcutaneous pembrolizumab and berahyaluronidase alfa-pmph for eligible pembrolizumab solid-tumor indications.
• 2025:FDA granted traditional approval to pembrolizumab with trastuzumab and chemotherapy for qualifying HER2-positive, PD-L1-positive advanced gastric or GEJ adenocarcinoma, based on KEYNOTE-811 involving 698 patients.

Research Methodology

The analysis uses the supplied 2025, 2026, and 2034 numerical tables as the mandatory primary source for revenue, segment contribution, and CAGR calculations. Cancer-type totals of USD 4,929.84 million, USD 5,079.73 million, and USD 6,455.83 million were retained without alteration, while percentage contributions were calculated directly from supplied values. Diagnosis totals of USD 4,929.85 million in 2025, USD 5,086.06 million in 2026, and USD 6,528.18 million in 2034 were independently preserved because they differ from the cancer-type series. Public NCI and FDA information was used only for epidemiology, clinical context, regulatory developments, and treatment evidence; unavailable county, company-share, treatment-segment, stage, end-user, route, and distribution-channel values were not fabricated.